Tech Track 100

This Dundee University spin-out automates drug discovery and can shorten the pre-clinical stage by at least 75% — helping to bring treatments to market faster and at less cost. In January, it announced the first AI-“invented” drug molecule to begin human trials, and it is currently working with American medical research facility Scripps Research and the EU’s Innovative Medicines Initiative to discover new drugs for treatment of the coronavirus. Based in Oxford and led by founder Andrew Hopkins, 48, sales reached £9.1m last year, through working with pharmaceuticals giants such as Glaxo Smith Kline and Bristol Myers Squibb. The latter was involved in a $60m investment in May, alongside European life sciences companies Evotec and Novo Holdings.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2020
Rank31
CompanyExscientia
ActivityAI-driven drug discovery
LocationOxford
Average 3 year sales growth96.36%
Latest sales £000s9,107
Staff43
Founded2012
Websitewww.exscientia.co.uk

If applicable:

* supplied by company † annualised figure